Related Experiment Video

Updated: Jun 29, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.1K

BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in

Guang Lei1, Chao Mao1, Amber D Horbath1

  • 1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer Discovery
|March 29, 2024
PubMed

Insights

Breast cancer susceptibility gene 1 (BRCA1) deficiency causes resistance to certain ferroptosis inducers but creates vulnerability to others. Combining PARP and GPX4 inhibitors overcomes resistance in BRCA1-deficient cancers.

Area of Science:

  • Biochemistry
  • Cancer Biology
  • Drug Discovery

Background:

  • Poly (ADP-ribose) polymerase inhibitors (PARPi) are crucial for treating BRCA1-deficient cancers.
  • Resistance to PARPi limits treatment efficacy.
  • BRCA1's role in ferroptosis regulation is complex and not fully understood.

Purpose of the Study:

  • To elucidate the dual role of BRCA1 in ferroptosis regulation.
  • To investigate the mechanisms underlying PARPi resistance in BRCA1-deficient cancers.
  • To identify novel therapeutic strategies combining PARPi with other agents.

Main Methods:

  • Investigated BRCA1's regulation of VDAC3 and GPX4 transcription.
  • Assessed ferroptosis sensitivity to erastin and GPX4 inhibitors in BRCA1-deficient cells.
  • Analyzed NCOA4-mediated ferritinophagy and GPX4 induction.
  • Evaluated co-treatment efficacy of PARPi and GPX4 inhibitors in patient-derived xenografts.

Main Results:

  • BRCA1 deficiency promotes resistance to erastin-induced ferroptosis but sensitizes cells to GPX4 inhibitors.
  • NCOA4-mediated ferritinophagy and defective GPX4 induction enhance ferroptosis upon co-treatment.
  • BRCA1-mutant, PARPi-resistant tumors show decreased GPX4 and are sensitive to combined PARP and GPX4 inhibition.

Conclusions:

  • BRCA1 deficiency creates a specific ferroptosis vulnerability exploitable by combined PARP and GPX4 inhibition.
  • Targeting GPX4 can overcome PARPi resistance in BRCA1-deficient cancers.
  • This study provides a rationale for novel therapeutic combinations in breast cancer treatment.

More Related Videos

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA108:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

14.7K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K